 |
市場調査レポート
商品コード
1455152
ヒドロキシクロロキンの世界市場規模、シェア、成長分析、エンドユーザー別、流通チャネル別 - 産業予測2024年～2031年Global Hydroxychloroquine Market Size, Share, Growth Analysis, By End-User(Hospitals, Specialty Clinics), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy) - Industry Forecast 2024-2031 |
||||||
| ヒドロキシクロロキンの世界市場規模、シェア、成長分析、エンドユーザー別、流通チャネル別 - 産業予測2024年～2031年 |
|
出版日: 2024年03月17日
発行: SkyQuest
ページ情報: 英文 184 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
ヒドロキシクロロキンの世界市場規模は2022年に9,500億米ドルと評価され、予測期間（2024年～2031年）のCAGRは5.40%で、2023年の1兆米ドルから2031年には1兆5,300億米ドルに成長する見通しです。
同市場の目的は、これらの病気に苦しむ患者に効率的な治療ソリューションを提供し、症状の緩和、疾病管理、生活の質の向上を図ることです。ヒドロキシクロロキン市場の主な原動力の1つは、マラリア、関節リウマチ、ループスのような疾患の流行であり、これらは世界人口のかなりの部分を罹患しているため、治療アプローチとしてヒドロキシクロロキンを広く利用する必要があります。さらに、高齢者人口の増加とそれに伴う自己免疫疾患の増加が、ヒドロキシクロロキンの需要拡大に寄与しています。しかし、市場にはさまざまな阻害要因があります。網膜毒性や心不整脈など、ヒドロキシクロロキンに関連する安全性や潜在的な副作用に関する懸念が、医療従事者や患者の注意を促しています。さらに、ヒドロキシクロロキンの使用に関する規制上の制約やガイドライン、特に適応外処方のシナリオが市場拡大の課題となっています。ヒドロキシクロロキン市場はまた、代替治療オプションの利用可能性やマラリアの発生しやすい地域における薬剤耐性の出現といったハードルにも直面しています。とはいえ、世界のヒドロキシクロロキン市場は、マラリア、関節リウマチ、ループス、その他の自己免疫疾患を患う人々に効果的な治療の選択肢を提供するという重要な目的を担っています。課題にもかかわらず、ヒドロキシクロロキン市場の成長と発展を促進する可能性を秘めた、進行中の研究、臨床試験、共同研究の機会は豊富にあります。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- セカンダリおよびプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
ヒドロキシクロロキンの世界市場：エンドユーザー別
- 市場概要
- 病院
- 専門クリニック
- ホームケア
- その他
ヒドロキシクロロキンの世界市場：流通チャネル別
- 市場概要
- 病院薬局
- 小売薬局
- オンライン薬局
- その他
ヒドロキシクロロキンの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Sanofi（France）
- Novartis（Switzerland）
- Aurobindo Pharma（India）
- Dr. Reddy's Laboratories（India）
- Sun Pharmaceutical Industries（India）
- Cipla（India）
- Teva Pharmaceuticals（Israel）
- Hikma Pharmaceuticals（UK）
- Sandoz（Switzerland）
- Mylan（US）
- Apotex（Canada）
- Ranbaxy Laboratories（India）
- Torrent Pharmaceuticals（India）
- Lupin Pharmaceuticals（India）
- Zydus Cadila（India）
- Aurobindo Pharma USA（US）
- Novartis Pharmaceuticals Corporation（US）
- Sun Pharmaceutical Industries USA（US）
- Hikma Pharmaceuticals USA（US）
- Sandoz Inc.（US）
Global hydroxychloroquine market size was valued at USD 0.95 trillion in 2022 and is poised to grow from USD 1.00 trillion in 2023 to USD 1.53 trillion by 2031, at a CAGR of 5.40% during the forecast period (2024-2031).
The objective of the market is to offer an efficient therapeutic solution for patients grappling with these ailments, providing symptom relief, disease management, and enhanced quality of life. One of the primary driving forces behind the hydroxychloroquine market is the prevalence of diseases like malaria, rheumatoid arthritis, and lupus, which affect a substantial portion of the global population, necessitating widespread utilization of hydroxychloroquine as a treatment approach. Furthermore, the increasing elderly population and the consequent rise in autoimmune disorders contribute to the growing demand for hydroxychloroquine. However, the market encounters various restraining factors. Concerns regarding safety and potential side effects linked to hydroxychloroquine, such as retinal toxicity and cardiac arrhythmias, have prompted caution among healthcare practitioners and patients alike. Additionally, regulatory constraints and guidelines concerning hydroxychloroquine usage, particularly in off-label prescribing scenarios, pose challenges to market expansion. The hydroxychloroquine market also confronts hurdles such as the availability of alternative treatment options and the emergence of drug resistance in malaria-prone regions. Nevertheless, the global hydroxychloroquine market serves the crucial purpose of delivering effective treatment choices for individuals with malaria, rheumatoid arthritis, lupus, and other autoimmune disorders. Despite the challenges, opportunities abound in ongoing research, clinical trials, and collaborations, which have the potential to drive growth and advancement within the hydroxychloroquine market.
Top-down and bottom-up approaches were used to estimate and validate the size of the global hydroxychloroquine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Hydroxychloroquine Market Segmental Analysis
The global hydroxychloroquine market is segmented based on end-user, distribution channel, and region. By end-user, the market is segmented into hospitals, specialty clinics, homecare, and others. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Hydroxychloroquine Market
The global demand for hydroxychloroquine as a treatment for malaria remained a significant driver of market growth. Malaria is a widespread infectious disease, particularly prevalent in regions like Sub-Saharan Africa and Southeast Asia. Hydroxychloroquine has long been recognized as an effective antimalarial medication, contributing to its widespread usage. The continued efforts to combat malaria and the persistent need for effective treatment options further fueled the demand for hydroxychloroquine in 2022.
Restraints in the Global Hydroxychloroquine Market
The hydroxychloroquine market encountered a notable challenge stemming from safety concerns and regulatory restrictions linked to its usage. Various studies and reports spotlighting potential side effects, such as retinal toxicity and cardiac arrhythmias, prompted caution among healthcare professionals and regulatory bodies. Consequently, restrictions were imposed on the off-label utilization of hydroxychloroquine, accompanied by heightened scrutiny of its safety profile.
Market Trends of the Global Hydroxychloroquine Market
A noteworthy trend observed in the hydroxychloroquine market was the investigation of combination therapies. Researchers and healthcare professionals delved into the potential synergies of hydroxychloroquine when paired with other medications or treatment approaches. The objective was to improve treatment outcomes, mitigate side effects, and optimize therapeutic effectiveness across a range of disease conditions.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Hydroxychloroquine Market by End-User
- Market Overview
- Hospitals
- Specialty Clinics
- Homecare
- and Others
Global Hydroxychloroquine Market by Distribution Channel
- Market Overview
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- and Others
Global Hydroxychloroquine Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceuticals (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apotex (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ranbaxy Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Cadila (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma USA (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis Pharmaceuticals Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries USA (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals USA (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
